仿制药-话题@MedSci

#仿制药#

261篇内容 | 5558人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261494, encodeId=86e212614940c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据, objectType=article, longId=167617, objectId=95d816e61754, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95d816e61754, replyNumber=0, likeNumber=67, createdTime=2019-06-05, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95d816e61754, moduleTitle=2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95d816e61754)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261493, encodeId=1e8d1261493ef, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, objectType=article, longId=167495, objectId=7c2016e4958b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2016e4958b, replyNumber=0, likeNumber=73, createdTime=2019-06-03, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2016e4958b, moduleTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c2016e4958b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, objectType=article, longId=166718, objectId=55b4166e1844, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55b4166e1844, replyNumber=0, likeNumber=91, createdTime=2019-05-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55b4166e1844, moduleTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55b4166e1844)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261491, encodeId=36001261491b6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=美国各州对于被哄抬的仿制药药价，起诉20家制药公司, objectType=article, longId=166080, objectId=368816608081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=368816608081, replyNumber=0, likeNumber=67, createdTime=2019-05-16, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=368816608081, moduleTitle=美国各州对于被哄抬的仿制药药价，起诉20家制药公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=368816608081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261490, encodeId=4ede12614905d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Teva宣布在美国推出Delzicol（美沙拉嗪）延迟释放胶囊仿制药, objectType=article, longId=165918, objectId=9a23165918db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a23165918db, replyNumber=0, likeNumber=231, createdTime=2019-05-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a23165918db, moduleTitle=Teva宣布在美国推出Delzicol（美沙拉嗪）延迟释放胶囊仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a23165918db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261489, encodeId=29a0126148994, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=进口仿制药通过一致性评价, objectType=article, longId=165703, objectId=50df165e03d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50df165e03d9, replyNumber=0, likeNumber=62, createdTime=2019-05-10, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50df165e03d9, moduleTitle=进口仿制药通过一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50df165e03d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261488, encodeId=5fd012614882e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2019 临床建议：接受生物仿制药治疗的IBD患者反安慰剂效应的预防和管理, objectType=article, longId=164920, objectId=3b2d16492015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b2d16492015, replyNumber=0, likeNumber=23, createdTime=2019-04-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b2d16492015, moduleTitle=2019 临床建议：接受生物仿制药治疗的IBD患者反安慰剂效应的预防和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b2d16492015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261487, encodeId=6675126148e1f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=纳洛酮鼻腔喷雾剂仿制药获FDA批准，用于治疗阿片类药物服用过量, objectType=article, longId=164872, objectId=56031648e274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56031648e274, replyNumber=0, likeNumber=49, createdTime=2019-04-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56031648e274, moduleTitle=纳洛酮鼻腔喷雾剂仿制药获FDA批准，用于治疗阿片类药物服用过量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56031648e274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261486, encodeId=c6521261486e3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药市场有望升级，力扬实验室强势助攻, objectType=article, longId=164827, objectId=9fdb16482efc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fdb16482efc, replyNumber=0, likeNumber=46, createdTime=2019-04-24, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fdb16482efc, moduleTitle=仿制药市场有望升级，力扬实验室强势助攻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fdb16482efc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261485, encodeId=b5671261485b8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2019 PANLAR共识声明：生物仿制药, objectType=article, longId=164368, objectId=d8a61643685e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8a61643685e, replyNumber=0, likeNumber=30, createdTime=2019-04-17, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8a61643685e, moduleTitle=2019 PANLAR共识声明：生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8a61643685e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261484, encodeId=de671261484ed, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=全新仿制药一致性评价通过品规汇总：受理号破千通过数超200, objectType=article, longId=163263, objectId=27fb16326399, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27fb16326399, replyNumber=0, likeNumber=24, createdTime=2019-03-31, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27fb16326399, moduleTitle=全新仿制药一致性评价通过品规汇总：受理号破千通过数超200, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27fb16326399)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261483, encodeId=cbaf12614834b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=小议仿制药扩大临床药理学的可能性, objectType=article, longId=163098, objectId=8ab316309874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab316309874, replyNumber=0, likeNumber=56, createdTime=2019-03-29, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab316309874, moduleTitle=小议仿制药扩大临床药理学的可能性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab316309874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261482, encodeId=2ca11261482a3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=“4+7”带量采购新形势下，如何进行仿制药企业招商？（中篇）, objectType=article, longId=162706, objectId=536c162e063b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=536c162e063b, replyNumber=0, likeNumber=87, createdTime=2019-03-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=536c162e063b, moduleTitle=“4+7”带量采购新形势下，如何进行仿制药企业招商？（中篇）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=536c162e063b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261481, encodeId=441012614811b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功, objectType=article, longId=162030, objectId=356d1620300f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=356d1620300f, replyNumber=0, likeNumber=49, createdTime=2019-03-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=356d1620300f, moduleTitle=Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=356d1620300f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261480, encodeId=35f4126148072, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2018美国FDA仿制药批准报告：批准超1000个仿制药首仿药占10%, objectType=article, longId=161821, objectId=d8a2161821d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8a2161821d7, replyNumber=0, likeNumber=81, createdTime=2019-03-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8a2161821d7, moduleTitle=2018美国FDA仿制药批准报告：批准超1000个仿制药首仿药占10%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8a2161821d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261479, encodeId=4acf12614e944, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症, objectType=article, longId=161663, objectId=6e94161663bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e94161663bc, replyNumber=0, likeNumber=64, createdTime=2019-03-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e94161663bc, moduleTitle=Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e94161663bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261478, encodeId=8d3912614e890, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=西安鼓励企业研发仿制药，**可获200万元补助, objectType=article, longId=161515, objectId=52821615153e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52821615153e, replyNumber=0, likeNumber=81, createdTime=2019-03-03, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52821615153e, moduleTitle=西安鼓励企业研发仿制药，**可获200万元补助, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52821615153e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261477, encodeId=975512614e700, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=医生推荐患者购买印度仿制药被停职或还有牢狱之灾, objectType=article, longId=161381, objectId=7eed161381ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eed161381ba, replyNumber=0, likeNumber=63, createdTime=2019-03-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eed161381ba, moduleTitle=医生推荐患者购买印度仿制药被停职或还有牢狱之灾, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eed161381ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261476, encodeId=c8bb12614e63a, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药地位不容动摇, objectType=article, longId=161245, objectId=25ba161245b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ba161245b7, replyNumber=0, likeNumber=81, createdTime=2019-02-28, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ba161245b7, moduleTitle=仿制药地位不容动摇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ba161245b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261475, encodeId=60ec12614e54a, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=便宜又好用的肿瘤生物仿制药，你了解有多少？, objectType=article, longId=161238, objectId=ebcb16123867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebcb16123867, replyNumber=0, likeNumber=87, createdTime=2019-02-28, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebcb16123867, moduleTitle=便宜又好用的肿瘤生物仿制药，你了解有多少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebcb16123867)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据

2019-06-05

drwjr (审核中...)

前往app查看评论内容

#仿制药#

欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请

2019-06-03

drwjr (审核中...)

前往app查看评论内容

#仿制药#

加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌

2019-05-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

美国各州对于被哄抬的仿制药药价，起诉20家制药公司

2019-05-16

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Teva宣布在美国推出Delzicol（美沙拉嗪）延迟释放胶囊仿制药

2019-05-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

进口仿制药通过一致性评价

2019-05-10

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2019 临床建议：接受生物仿制药治疗的IBD患者反安慰剂效应的预防和管理

2019-04-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

纳洛酮鼻腔喷雾剂仿制药获FDA批准，用于治疗阿片类药物服用过量

2019-04-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药市场有望升级，力扬实验室强势助攻

2019-04-24

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2019 PANLAR共识声明：生物仿制药

2019-04-17

drwjr (审核中...)

前往app查看评论内容

#仿制药#

全新仿制药一致性评价通过品规汇总：受理号破千通过数超200

2019-03-31

drwjr (审核中...)

前往app查看评论内容

#仿制药#

小议仿制药扩大临床药理学的可能性

2019-03-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

“4+7”带量采购新形势下，如何进行仿制药企业招商？（中篇）

2019-03-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功

2019-03-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2018美国FDA仿制药批准报告：批准超1000个仿制药首仿药占10%

2019-03-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症

2019-03-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

西安鼓励企业研发仿制药，**可获200万元补助

2019-03-03

drwjr (审核中...)

前往app查看评论内容

#仿制药#

医生推荐患者购买印度仿制药被停职或还有牢狱之灾

2019-03-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药地位不容动摇

2019-02-28

drwjr (审核中...)

前往app查看评论内容

#仿制药#

便宜又好用的肿瘤生物仿制药，你了解有多少？

2019-02-28

科室
- - 订阅+
  - 更多科室
工具
服务